#United States #New York #Securities Class Action #uniQure N.V. #AMT-130

uniQure Shareholder Alert: Crucial Deadline Approaching

In a significant development for investors of uniQure N.V. (NasdaqGS: QURE), ClaimsFiler, a service specializing in shareholder information, has issued a vital reminder. Shareholders who have incurred losses exceeding $100,000 during the specified Class Period - from September 24, 2025, to October 31, 2025 - must act swiftly. They have until April 13, 2026, to submit their lead plaintiff applications in a pending class action lawsuit against the pharmaceutical company.

Background of the Lawsuit

The lawsuit against uniQure, currently being processed in the United States District Court for the Southern District of New York, stems from allegations that the company and its executives failed to disclose critical information to investors. According to the complaint, uniQure misled investors regarding the approval process of its leading drug candidate, AMT-130.

During the Class Period, uniQure claimed that there was a strong possibility for AMT-130 to receive expedited approval from the U.S. Food and Drug Administration (FDA) following its planned submission for Biologics License Application (BLA) in early 2026. However, this optimistic scenario shifted dramatically. On November 3, 2025, the company disclosed that the FDA had expressed concerns. The agency stated that the data from initial Phase I/II studies of AMT-130, compared against an external control, might not be sufficient to substantiate a BLA submission.

As a result of this revelation, uniQure’s stock price plummeted by $33.40, or over 49%, just within a few days, diminishing from $67.69 on October 31, 2025, to $34.29 by November 3, 2025. This drop not only reflects the shock of shareholders but also highlights the intense scrutiny that the company now faces regarding its disclosure practices and corporate governance.

Next Steps for Affected Investors

Investors who feel impacted by uniQure's disclosure issues are encouraged to seek legal guidance early. They can either visit ClaimsFiler at claimsfiler.com or contact their support line toll-free at 844-367-9658. Legal representatives from Kahn Swick & Foti, LLC, are available to discuss potential avenues for recovery.

ClaimFiler's mission is to empower retail investors to reclaim their fair share from securities class action settlements, providing valuable resources and insights into ongoing legal matters. By registering on their platform, investors can gain access to important case updates and potential settlement notifications, ensuring they remain informed and engaged with relevant class action proceedings.

The Importance of Timely Action

The approaching lead plaintiff deadline is a clear signal for affected investors to take action. ClaimsFiler’s alert serves as a critical reminder that failing to file by the stipulated deadline could prevent investors from participating in potential recoveries linked to this significant lawsuit. Given the substantial financial losses that many shareholders might experience, awareness and proactive steps are essential.

As developments unfold, the legal landscape for uniQure will be closely monitored. The situation underlines the importance of transparency within the pharmaceutical industry and highlights how investor rights must be safeguarded within the legal framework. In a rapidly evolving market, informed investors can make a difference not only for themselves but also in promoting accountability in publicly traded companies like uniQure.

Conclusion

In summary, uniQure shareholders with substantial financial losses have a limited time to prepare their legal strategy. The upcoming April 13, 2026 deadline is a pivotal date that could determine the potential recovery for many shareholders. By staying informed and taking necessary legal steps, investors can protect their interests amidst this tumultuous situation.